Anton Porsteinsson
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Alzheimer Disease | 27 | 1997 | 71 |
Why?
|
Valproic Acid | 9 | 1997 | 26 |
Why?
|
Dementia | 7 | 1997 | 56 |
Why?
|
Psychomotor Agitation | 8 | 1997 | 11 |
Why?
|
Memantine | 2 | 2007 | 8 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2007 | 21 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 3 | 2003 | 38 |
Why?
|
Cholinesterase Inhibitors | 5 | 2000 | 11 |
Why?
|
Cognition Disorders | 7 | 2008 | 107 |
Why?
|
Aged | 34 | 1996 | 988 |
Why?
|
Neuropsychological Tests | 7 | 2000 | 113 |
Why?
|
Mental Disorders | 6 | 1996 | 132 |
Why?
|
Sertraline | 4 | 2006 | 6 |
Why?
|
Psychotropic Drugs | 4 | 1997 | 30 |
Why?
|
Aged, 80 and over | 17 | 1996 | 599 |
Why?
|
Serotonin Uptake Inhibitors | 4 | 2002 | 19 |
Why?
|
Double-Blind Method | 12 | 2000 | 274 |
Why?
|
Neuroprotective Agents | 5 | 2002 | 60 |
Why?
|
Aging | 1 | 2009 | 275 |
Why?
|
Depressive Disorder | 4 | 2006 | 76 |
Why?
|
Humans | 37 | 1996 | 1856 |
Why?
|
Depression | 6 | 2001 | 118 |
Why?
|
Antimanic Agents | 2 | 2001 | 7 |
Why?
|
Enzyme Inhibitors | 2 | 2003 | 216 |
Why?
|
Severity of Illness Index | 5 | 2000 | 358 |
Why?
|
Female | 25 | 1996 | 1643 |
Why?
|
Psychotic Disorders | 3 | 2003 | 38 |
Why?
|
Male | 24 | 1996 | 1553 |
Why?
|
Antidepressive Agents | 2 | 2010 | 46 |
Why?
|
Activities of Daily Living | 4 | 2000 | 122 |
Why?
|
Drug Therapy, Combination | 3 | 1997 | 189 |
Why?
|
Anticonvulsants | 4 | 2001 | 61 |
Why?
|
Cognition | 3 | 2000 | 97 |
Why?
|
Mental Status Schedule | 5 | 2005 | 13 |
Why?
|
Antipsychotic Agents | 4 | 2003 | 49 |
Why?
|
GABA Agents | 1 | 1997 | 1 |
Why?
|
Treatment Outcome | 10 | 2000 | 661 |
Why?
|
Street Drugs | 1 | 1997 | 16 |
Why?
|
Alcoholism | 1 | 1997 | 51 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2000 | 431 |
Why?
|
Substance-Related Disorders | 1 | 1997 | 96 |
Why?
|
Middle Aged | 10 | 1996 | 1161 |
Why?
|
Principal Component Analysis | 2 | 2010 | 18 |
Why?
|
Disease Progression | 3 | 2008 | 244 |
Why?
|
Behavioral Symptoms | 2 | 2000 | 10 |
Why?
|
Inositol | 1 | 2011 | 15 |
Why?
|
Suicide | 1 | 1997 | 60 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2011 | 48 |
Why?
|
Discriminant Analysis | 1 | 2010 | 21 |
Why?
|
Galantamine | 1 | 2000 | 1 |
Why?
|
Propylamines | 1 | 2009 | 4 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2009 | 14 |
Why?
|
Spiro Compounds | 1 | 2008 | 2 |
Why?
|
Diabetes Complications | 1 | 2009 | 49 |
Why?
|
Prospective Studies | 3 | 2005 | 545 |
Why?
|
Brief Psychiatric Rating Scale | 2 | 2003 | 10 |
Why?
|
Naproxen | 1 | 2008 | 4 |
Why?
|
Quinolones | 1 | 2008 | 17 |
Why?
|
Indoles | 1 | 2008 | 69 |
Why?
|
Pyrazoles | 1 | 2008 | 42 |
Why?
|
Psychiatric Status Rating Scales | 4 | 2005 | 99 |
Why?
|
Piperazines | 1 | 2008 | 57 |
Why?
|
Sulfonamides | 1 | 2008 | 74 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 78 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2006 | 13 |
Why?
|
Caregivers | 2 | 2003 | 50 |
Why?
|
Azepines | 1 | 2006 | 10 |
Why?
|
Clinical Trials as Topic | 3 | 2001 | 251 |
Why?
|
Alanine | 1 | 2006 | 32 |
Why?
|
Endopeptidases | 1 | 2006 | 46 |
Why?
|
Placebos | 4 | 2001 | 110 |
Why?
|
Psychoanalytic Interpretation | 1 | 2005 | 5 |
Why?
|
Obesity | 1 | 2009 | 149 |
Why?
|
Risk Factors | 5 | 1997 | 555 |
Why?
|
Proportional Hazards Models | 3 | 2009 | 123 |
Why?
|
Social Control, Formal | 1 | 2003 | 7 |
Why?
|
Long-Term Care | 1 | 2003 | 38 |
Why?
|
Benzodiazepines | 1 | 2002 | 22 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 34 |
Why?
|
Depressive Disorder, Major | 2 | 1997 | 36 |
Why?
|
Apolipoprotein E4 | 2 | 2009 | 4 |
Why?
|
Time Factors | 4 | 2001 | 896 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 141 |
Why?
|
Calcium | 1 | 2007 | 208 |
Why?
|
Epilepsy | 1 | 2001 | 49 |
Why?
|
Follow-Up Studies | 3 | 2006 | 553 |
Why?
|
Educational Status | 2 | 2010 | 99 |
Why?
|
Regression Analysis | 1 | 2001 | 256 |
Why?
|
Patient Dropouts | 2 | 2006 | 24 |
Why?
|
Analysis of Variance | 1 | 2001 | 339 |
Why?
|
Questionnaires | 1 | 2003 | 360 |
Why?
|
Neurotransmitter Agents | 1 | 1997 | 30 |
Why?
|
Longitudinal Studies | 2 | 2008 | 195 |
Why?
|
Thyroid Function Tests | 1 | 1996 | 13 |
Why?
|
Reproducibility of Results | 2 | 2010 | 391 |
Why?
|
Thyrotropin | 1 | 1996 | 16 |
Why?
|
Cause of Death | 1 | 1997 | 82 |
Why?
|
Nursing Homes | 2 | 2005 | 55 |
Why?
|
Patient Care Team | 1 | 1997 | 119 |
Why?
|
Geriatric Assessment | 2 | 2001 | 63 |
Why?
|
Comorbidity | 1 | 1997 | 190 |
Why?
|
Magnetic Resonance Imaging | 2 | 2011 | 294 |
Why?
|
Mood Disorders | 2 | 2002 | 31 |
Why?
|
Social Support | 2 | 2003 | 111 |
Why?
|
Signal Transduction | 1 | 2002 | 313 |
Why?
|
Age Factors | 2 | 2001 | 480 |
Why?
|
New York | 1 | 1997 | 422 |
Why?
|
Atrophy | 1 | 2011 | 41 |
Why?
|
Amyloid beta-Peptides | 1 | 2011 | 24 |
Why?
|
Stroop Test | 1 | 2010 | 2 |
Why?
|
Word Association Tests | 1 | 2010 | 4 |
Why?
|
Trail Making Test | 1 | 2010 | 8 |
Why?
|
Apathy | 1 | 2010 | 1 |
Why?
|
Delusions | 1 | 2010 | 5 |
Why?
|
Verbal Behavior | 1 | 2010 | 23 |
Why?
|
Hallucinations | 1 | 2010 | 12 |
Why?
|
Administration, Oral | 1 | 2011 | 170 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 32 |
Why?
|
Reading | 1 | 2010 | 17 |
Why?
|
Cross-Cultural Comparison | 1 | 2010 | 27 |
Why?
|
Observer Variation | 1 | 2010 | 103 |
Why?
|
Medication Adherence | 1 | 2010 | 19 |
Why?
|
Statistics as Topic | 1 | 2010 | 133 |
Why?
|
Memory | 1 | 2010 | 61 |
Why?
|
PubMed | 1 | 2009 | 2 |
Why?
|
Space Perception | 1 | 2010 | 36 |
Why?
|
Peptide Fragments | 1 | 2011 | 144 |
Why?
|
Psychometrics | 1 | 2010 | 97 |
Why?
|
Body Weight | 1 | 2000 | 178 |
Why?
|
Overweight | 1 | 2009 | 28 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 179 |
Why?
|
Patient Compliance | 1 | 2010 | 113 |
Why?
|
Drug Toxicity | 1 | 2008 | 16 |
Why?
|
Animals | 2 | 2002 | 1031 |
Why?
|
Outcome Assessment (Health Care) | 1 | 2011 | 163 |
Why?
|
Multivariate Analysis | 1 | 2010 | 225 |
Why?
|
Confidence Intervals | 1 | 2008 | 104 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 321 |
Why?
|
Body Mass Index | 1 | 2009 | 122 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2008 | 64 |
Why?
|
United States | 2 | 2003 | 604 |
Why?
|
Sex Factors | 1 | 2010 | 284 |
Why?
|
Communication | 1 | 2010 | 116 |
Why?
|
Glucose | 1 | 2009 | 120 |
Why?
|
Prognosis | 1 | 2010 | 388 |
Why?
|
Problem Solving | 1 | 2006 | 39 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2006 | 11 |
Why?
|
Affect | 1 | 2006 | 55 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2006 | 16 |
Why?
|
Counseling | 1 | 2006 | 50 |
Why?
|
Outpatients | 1 | 2005 | 29 |
Why?
|
Quality of Life | 1 | 2010 | 188 |
Why?
|
Cost of Illness | 1 | 2006 | 54 |
Why?
|
Insulin | 1 | 2009 | 129 |
Why?
|
Homes for the Aged | 1 | 2005 | 25 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 83 |
Why?
|
Adult | 2 | 1996 | 1317 |
Why?
|
Combined Modality Therapy | 1 | 2006 | 219 |
Why?
|
Primary Health Care | 1 | 2010 | 151 |
Why?
|
Clinical Protocols | 1 | 2005 | 93 |
Why?
|
Research Design | 1 | 2006 | 169 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 191 |
Why?
|
Pilot Projects | 1 | 2005 | 264 |
Why?
|
Ginkgo biloba | 1 | 2003 | 3 |
Why?
|
Phytotherapy | 1 | 2003 | 12 |
Why?
|
Homocysteine | 1 | 2003 | 14 |
Why?
|
Drug Evaluation | 1 | 2003 | 54 |
Why?
|
Brain | 1 | 2011 | 305 |
Why?
|
Plant Extracts | 1 | 2003 | 22 |
Why?
|
Professional-Family Relations | 1 | 2003 | 35 |
Why?
|
Vitamin E | 1 | 2003 | 38 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 34 |
Why?
|
Retrospective Studies | 1 | 2009 | 653 |
Why?
|
Anti-Inflammatory Agents | 1 | 2003 | 80 |
Why?
|
Child, Preschool | 2 | 1996 | 554 |
Why?
|
Diagnosis, Differential | 1 | 2005 | 402 |
Why?
|
Decision Making | 1 | 2003 | 130 |
Why?
|
Sleep Disorders | 1 | 2001 | 32 |
Why?
|
Research | 1 | 2001 | 124 |
Why?
|
Child | 2 | 1996 | 749 |
Why?
|
Patient Selection | 1 | 2001 | 155 |
Why?
|
Adolescent | 2 | 1996 | 891 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2001 | 176 |
Why?
|
Thyroxine | 1 | 1996 | 26 |
Why?
|
Triiodothyronine | 1 | 1996 | 23 |
Why?
|
Thyroid Diseases | 1 | 1996 | 19 |
Why?
|
Cost-Benefit Analysis | 1 | 1996 | 118 |
Why?
|
Infant | 1 | 2001 | 464 |
Why?
|
Mass Screening | 1 | 1996 | 125 |
Why?
|
Hospitalization | 1 | 1996 | 169 |
Why?
|
